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A B S T R A C T
Fabry Disease (FD) is a multisystemic X-linked disorder that belongs to the group of lysosomal storage disorders (LSDs). Causal mutations on alpha-galactosidase A
(α-Gal A) commonly lead to abnormal protein and consequently to FD. Since it is an X-linked disease, males are primarily affected. This work describes the generation
of induced Pluripotent Stem Cells (iPSCs) from skin fibroblasts from a FD patient, using non-integrative episomal vectors. Differentiation of iPSCs can be applied to
generate a variety of cell types with high degree of genetic complexity that would otherwise be difficult to obtain.
Resource table










Type of cell line iPSC
Origin Human
Additional origin info Age:
Sex: male




Epi5 Episomal iPSC Reprogramming Kit
Genetic Modification Yes
Type of Modification Familial
Associated disease Fabry Disease
Gene/locus FD gene (Gene ID: 2717)/locus Xq22.1; Mutation in
hemizygosity; p.W287X (rs104894839)
Method of modification Not applicable











The cell line has not been deposited in a stem cell bank or
repository but is physically cryopreserved at INSA's facil-
ities in CSPGF in Porto, Portugal.
Ethical approval Original fibroblast line was obtained from a non-com-
mercial provider, Gaslini Istitute Biobank under Genetic
Biobank Guidelines, Telethon - SIGU, Analysis 4/5, 2003.
Italian Data Protection Authority (Garante Privacy),
General Authorization for the processing of gene data n°8/
2016. INSA project approval code 2015DGH1073.
1. Resource utility
In this work, we report the establishment of an iPSC line from a
Fabry disease (FD) patient. The starting biological material was skin
fibroblasts. Skin biopsies are not difficult to get and provide an easy to
obtain material for generating iPSCs. The development of iPSCs and its
application to the LSD field is contributing significantly to new strate-
gies for pathogenesis modeling and drug testing.
This report presents the establishment of iPSCs derived from Fabry
disease (FD, ORPHA324, OMIM:301,500) patient's fibroblasts. FD is one
of the most common LSDs, it is X-linked and caused by mutations in the
alpha-galactosidase A gene (GLA, Xq21.3-q22, OMIM: 300,644), which
lead to the pathogenic deficient activity of the lysosomal hydrolase
alpha-galactosidase A (α-Gal A, EC 3.2.1.22). This deficiency results in
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progressive accumulation of glycolipids and in the subsequent mal-
function of the cells affected (for example, podocytes and cardiomyo-
cytes). The iPSC line INSAi002-A was successfully generated from skin
fibroblasts from a hemizygous FD patient with a rare nonsense muta-
tion, p.W287X (Fig. 1). This mutation was first described in a patient
with classic clinical manifestations (Davies et al., 1993). A nonsense
point-mutation consisting of a TGG-to-TGA substitution in exon 6 of the
GLA gene (NM_000169.2:c.861G>A) results in p.W287X harboring a
stop codon predicting a premature termination of the α-Gal A and
possibly a truncated protein. Furthermore, exon 6 mutations have been
reported to be associated with cardiac variant phenotypes
(Takata et al., al.,1997). This INSAi002-A can be used for reprogram-
ming into specific cell types of interest and can be of particular im-
portance for the derivation of cardiomyocytes and modeling for me-
chanistic studies of the readthrough response to inducer compounds
(Lombardi et al., 2020).
Fig. 1. Characterization of induced pluripotent stem cell line (INSAi002-A) from a Fabry Disease patient hemizygote for the rare pW287X mutation.
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All results are summarized in Fig. 1. The fibroblasts were repro-
grammed using non-integrative episomal vectors co-expressing the re-
programming genes Oct4, Sox2, Klf4, L-Myc, and Lin28, on a feeder-free
system with vitronectin. Formation of iPSC-like colonies were clearly
observable 24 days after transfection of the reprogramming vectors into
FD fibroblasts (Fig. 1A). A typical human pluripotent stem cell-like
morphology was detected by 30 days after transfection (Fig. 1A). A
clone of FD-derived iPSC chosen to be better characterized, termed
INSAi002-A cell line, showed the expression of endogenous plur-
ipotency markers such as NANOG, SOX2, OCT4 and TRA-1–60 detected
by immunofluorescence (Fig. 1B). A quantitative analysis by RT-qPCR
of OCT4 expression showed an elevated expression in INSAi002-A cells
in comparison to control fibroblasts (Fig. 1C), indicating further that
INSAi002-A cells were reprogrammed. The INSAi002-A iPSCs retained
the FD-causing GLA mutation (Fig. 1D) and displayed a normal 46XY
karyotype (Fig. 1G) . In addition, these cells were devoid of any of the
episomal vectors integration, as confirmed by RT-qPCR using primers
specific for the vectors (Fig. 1E). In addition, The INSAi002-A iPSCs
differentiated into all three germ layers as indicated by the positive
immunofluorescence detection of mesoderm (BRACHYURY), endoderm
(SOX17) and ectoderm (OTX2) markers, revealing their pluripotent
nature (Fig. 1F). Altogether, the observations mentioned above along
with STR analysis, indicated an efficient iPSCs production preserving
the original genetic characteristics of the donor fibroblasts, using epi-
somal vectors under feeder free conditions.
2. Materials and methods
2.1. Biological sample
The skin fibroblasts cell line from FD patient was obtained from
Istituto Giannina Gaslini Bioresource Bank (Genova, Italy) in com-
pliance with the ethical recommendations issued by the Ovideo
agreement of 1997 and the International Declaration on Human
Genetics Data of 2003 (Filocamo et al., 2014). The FD cell line was from
a hemizygous male patient bearing the nonsense mutation p.W287X
(rs104894839).
2.2. Fibroblasts culture
Cells were maintained in DMEM (1X) + GlutaMAX medium (Gibco)
supplemented with 10% fetal bovine serum and 1% PEN-STREP (Lonza
BioWhittaker) 5000 U Penicilin/mL in an incubator.
2.3. Reprogramming of fibroblasts to iPSCs
Cellular reprogramming fibroblasts to iPSCs was carried out using a
non-integrative approach using episomal vectors. Fibroblasts were
plated in 6-well plates coated with vitronectin, once confluences around
75% were reached transfection was performed. We used the Epi5
Episomal iPSC Reprogramming Kit (Invitrogen) on skin fibroblasts. The
Epi5 iPSC kit contains an optimized mixture of three episomal vectors
with an oriP/EBNA-1 (Epstein-Barr nuclear antigen-1) backbone for
delivering the reprogramming genes Oct4, Sox2, Klf4, L-Myc, and
Lin28. Additionally, it uses an optimized mixture of two vectors ex-
pressing mp53DD (a dominant negative mutation of p53) and EBNA1,
which together improve the reprogramming efficiency of the system.
The silencing of the viral promoter driving EBNA-1 expression, the loss
of the episomes at a rate of approximately 5% per cell cycle due to
defects in vector synthesis, and partitioning allows the removal of
episomal vectors from the iPSCs without any additional manipulation
The transfection of cells was done with Lipofectamine 3000
(Invitrogen) in Opti-MEM medium (Gibco).. Around 24 days after
transfection, iPSC-like colonies were observed and were manually
picked for further expansion and characterization. The cell culture
matrix used for iPSCs growth was Vitronectin (VTNN from Gibco).
2.4. Cell culture and passage
Cells were cultured in 60 mm plates coated with 1/100 VTNeN
diluted in 1X DPBS, and the incubator was at 37 °C with 5% CO2. Once
high confluence was reached, the medium was removed, cells were
washed with 1X DPBS and treated with 1 mL of 0,5 mM EDTA solution
for 4 min at room temperature for iPSCs detachment. After iPSCs de-
tachment, EDTA is removed and iPSCs passage is done through re-
suspension of the cells with supplemented Gibco StemFlex Medium and
1% PEN-STREP (Lonza BioWhittaker) 5000 U Penicilin/mL. To the new
matrix treated dishes is added 50 µL of cell suspension in a 2 mL volume
medium.
2.5. Detection of episomal vectors by PCR in iPSCs
DNA samples were extracted from cell pellets using QIAamp® DNA
Blood Mini Kit (Qiagen). Detection of the presence of Episomal iPSC
Reprogramming Vectors in reprogrammed iPSC colonies was done by
PCR using the PCR primers listed on Table 1. The EBNA-1 primer set
can detect all five episomal plasmids in the kit. The oriP primer set can
detect all episomal plasmids in the kit except pCXB-EBNA1, which lacks
the OriP gene. After 9 passages, no episomal vectors were detected on
FD iPSCs using PCR, indicating that our iPSCs were free of vectors
footprint. Characterization and validation is shown in Fig. 1 and
Table 1.
2.6. Pluripotency characterization
To characterize the iPSCs obtained, we have used the Fluorescent
Table 1.
Characterization and validation.
Classification Test Result Data
Morphology Light microscopy Photography Normal Fig. 1 panel A (morphology of a typical colony 24 (left) and
32 days (right) post-transduction with reprogramming
vectors
Phenotype Qualitative analysis Immunofluorescence
(IF)
Positive for NANOG, SOX2, OCT4 and
TRA-1-60
Fig. 1 panel B
Quantitative analysis (RT-qPCR) Positive for OCT4 Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution 46XY, Resolution 450–500 Fig. 1 panel G
Identity STR analysis DNA Profiling Performed Supplementary file
Mutation analysis Sequencing Hemizygous p.W287X (rs104894839) Fig. 1 panel D
Microbiology and
virology
Mycoplasma Mycoplasma testing by RT-PCR: Negative Not presented
Sendai RT-PCR analysis: Negative Fig. 1 panel E
Differentiation potential Embryoid body formation and Directed
differentiation (IF)
Positive detection of 3 germ layers
markers BRACHYURY, SOX17 and OTX2
Fig. 1 panel F
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Human ES/iPS Cell Characterization Kit (Merk Milipore). This kit in-
cludes conjugated antibodies to study pluripotent transcription factors:
Oct-4, Sox-2 and Nanog; and cell surface epitopes, TRA-1–60. The
qualitative analysis by immunofluorescence showed positive staining
for all pluripotency markers confirming the pluripotent status.
2.7. Genetic characterization
Genotype was established in fibroblasts and in iPSCs and the mu-
tations confirmed (Fig. 1D). See Table 2 for primers used. PCR products
were purified with the ExoSAP-IT (Applied Biosystems), for Sanger
sequencing BigDye®Terminator v3.1 (Applied Biosystems) was use. STR
analysis used the AmpFeSTR® Identifier® (Applied Biosystems).
Karyotyping was performed on G-banded metaphase chromosomes
using standard procedures and at least four metaphases were examined
per sample. The result of the karyotype analysis was a normal 46XY
(Fig. 1G).
2.8. iPSCs differentiation into the three germ layers
To determine if a cell is truly a pluripotent stem cell, it is important
to verify its ability to differentiate into each of the three germ layers.
We used the Human Pluripotent Stem Cell Functional Identification Kit
(R&D Systems®) to differentiate into endoderm and ectoderm. In ad-
dition, we used the Differentiation Base Media Supplement (50X), that
comes with this kit, with CHIR99021 supplement (Stemcell
Technologies), a WNT pathway activator that promotes direct meso-
derm differentiation. We used antibodies against OTX2, BRACHYURY,
and SOX17 (ectoderm, mesoderm and endoderm markers, respec-
tively), for the immunocytochemical studies (Fig. 1F). In brief, seeded
iPSCs were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 10 min,
incubated with PBST with 1% BSA (Sigma-Aldrich) for 30 min and
stained by standard immunofluorescence procedures. Cells were ana-
lyzed on DM400 M fluorescence microscope (Leica). Antibodies are
listed in Table 2.
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Table 2.
Reagent details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-Nanog, clone 7F7.1, Alexa Fluor® 488 conjugate 1:100 Millipore Cat# MABD24, RRID:AB_11203826
Mouse anti-Sox-2, clone 10H9.1, Cy3 conjugate 1:100 Millipore Cat# MAB4423, RRID:AB_11205572
Mouse anti-Oct-4 (POU5f1), clone 7F9.2, Alexa Fluor® 488 conjugate 1:100 Millipore Cat# MAB4419, RRID:AB_1977399
Mouse anti-TRA-1-60, clone TRA-1-60, Cy3 conjugate 1:100 Millipore Cat# MAB4360, RRID:AB_2119183
Germ Layer Markers Goat Anti-Human Brachyury Polyclonal Antibody, unconjugated (Mesoderm) 1:10 R and D Systems Cat# AF2085, RRID:AB_2200235
Goat Anti-Human Sox17 Polyclonal Antibody, unconjugated (Endoderm) 1:10 R and D Systems Cat# AF1924, RRID:AB_355060
Goat Anti-Human Otx2 Polyclonal Antibody, unconjugated (Ectoderm) 1:10 R and D Systems Cat# AF1979, RRID:AB_2157172
Secondary antibodies Donkey anti-Goat IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor
488
1:200 Thermo Fisher Scientific Cat# A-11055, RRID:AB_2534102
Primers
Target TaqMan® assay
Pluripotency Marker (qPCR) OCT-4 hs00999632_g1
House-Keeping Gene (qPCR) GAPDH hs02786624_g1
Target Forward/Reverse primer (5′−3′)
Targeted mutation sequencing GLA exon 6 CCTGCGGTAGGCTTGTT/AGGCCCAAGACAAAGTT
Epissomal Vectors OriP TTCCACGAGGGTAGTGAACC/TCGGGGGTGTTAGAGACAAC
EBNA-1 ATCGTCAAAGCTGCACACAG/CCCAGGAGTCCCAGTAGTCA
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